Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Samuel Egieyeh

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Viruses|October 26, 2021
A Perspective on Nanotechnology and COVID-19 Vaccine Research and Production in South AfricaAdmire Dube, Samuel Egieyeh, Mohammed Balogun
Clinical Pharmacology and Therapeutics|August 21, 2024
Progress in Pharmacometrics Implementation and Regulatory Integration in Africa: A Systematic ReviewBonginkosi S'fiso Ndzamba, Samuel Egieyeh, Pius Fasinu
Molecules (Basel, Switzerland)|January 20, 2016
Exploration of Scaffolds from Natural Products with Antiplasmodial Activities, Currently Registered Antimalarial Drugs and Public Malarial Screen DataSamuel Egieyeh, James Syce, Alan Christoffels, et al.
Plos One|September 29, 2018
Predictive classifier models built from natural products with antimalarial bioactivity using machine learning approachSamuel Egieyeh, James Syce, Sarel F Malan, et al.
Expert Opinion on Therapeutic Patents|June 14, 2024
HDAC3 inhibitors: a patent review of their broad-spectrum applications as therapeutic agentsThabo Brighton Makgoba, Erika Kapp, Samuel Egieyeh, et al.
Chemical Biology & Drug Design|December 1, 2021
In silico design, chemical synthesis and biological screening of novel 4-(1H)-pyridone-based antimalarial agentsOluwatosin Audu, Andre Stander, Olayinka Ajani, et al.
Plos One|January 8, 2021
Computational drug repurposing strategy predicted peptide-based drugs that can potentially inhibit the interaction of SARS-CoV-2 spike protein with its target (humanACE2)Samuel Egieyeh, Elizabeth Egieyeh, Sarel Malan, et al.
BMC Pharmacology & Toxicology|November 25, 2023
In-silico and in-vitro screening of Asiatic acid and Asiaticoside A against Cathepsin S enzymeTemitope Akinwumi Ajani, Kenechukwu Obikeze, Zandisiwe E Magwebu, et al.
Antioxidants (Basel, Switzerland)|February 25, 2022
Alpha-Glucosidase and Alpha-Amylase Inhibitory Activities, Molecular Docking, and Antioxidant Capacities of <i>Plectranthus ecklonii</i> ConstituentsNinon G E R Etsassala, Jelili A Badmus, Jeanine L Marnewick, et al.
Tuberculosis (Edinburgh, Scotland)|May 27, 2023
Discovery and biological evaluation of an adamantyl-amide derivative with likely MmpL3 inhibitory activityErika Kapp, Hanri Calitz, Elizabeth M Streicher, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Viruses|October 26, 2021
A Perspective on Nanotechnology and COVID-19 Vaccine Research and Production in South AfricaAdmire Dube, Samuel Egieyeh, Mohammed Balogun
Clinical Pharmacology and Therapeutics|August 21, 2024
Progress in Pharmacometrics Implementation and Regulatory Integration in Africa: A Systematic ReviewBonginkosi S'fiso Ndzamba, Samuel Egieyeh, Pius Fasinu
Molecules (Basel, Switzerland)|January 20, 2016
Exploration of Scaffolds from Natural Products with Antiplasmodial Activities, Currently Registered Antimalarial Drugs and Public Malarial Screen DataSamuel Egieyeh, James Syce, Alan Christoffels, et al.
Plos One|September 29, 2018
Predictive classifier models built from natural products with antimalarial bioactivity using machine learning approachSamuel Egieyeh, James Syce, Sarel F Malan, et al.
Expert Opinion on Therapeutic Patents|June 14, 2024
HDAC3 inhibitors: a patent review of their broad-spectrum applications as therapeutic agentsThabo Brighton Makgoba, Erika Kapp, Samuel Egieyeh, et al.
Chemical Biology & Drug Design|December 1, 2021
In silico design, chemical synthesis and biological screening of novel 4-(1H)-pyridone-based antimalarial agentsOluwatosin Audu, Andre Stander, Olayinka Ajani, et al.
Plos One|January 8, 2021
Computational drug repurposing strategy predicted peptide-based drugs that can potentially inhibit the interaction of SARS-CoV-2 spike protein with its target (humanACE2)Samuel Egieyeh, Elizabeth Egieyeh, Sarel Malan, et al.
BMC Pharmacology & Toxicology|November 25, 2023
In-silico and in-vitro screening of Asiatic acid and Asiaticoside A against Cathepsin S enzymeTemitope Akinwumi Ajani, Kenechukwu Obikeze, Zandisiwe E Magwebu, et al.
Antioxidants (Basel, Switzerland)|February 25, 2022
Alpha-Glucosidase and Alpha-Amylase Inhibitory Activities, Molecular Docking, and Antioxidant Capacities of <i>Plectranthus ecklonii</i> ConstituentsNinon G E R Etsassala, Jelili A Badmus, Jeanine L Marnewick, et al.
Tuberculosis (Edinburgh, Scotland)|May 27, 2023
Discovery and biological evaluation of an adamantyl-amide derivative with likely MmpL3 inhibitory activityErika Kapp, Hanri Calitz, Elizabeth M Streicher, et al.
Pageof 1